Lung Cancers Treated With Photodynamic Therapy and Surgery by Okunaka, Tetsuya et al.
Diagnostic and Therapeutic Endoscopy, Vol. 5, pp. 155-160
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1999 OPA (Overseas Publishers Association) N.V.
Published by license under
the Harwood Academic Publishers imprint,
part of The Gordon and Breach Publishing Group.
Printed in Malaysia.
Lung Cancers Treated with Photodynamic Therapy
and Surgery
TETSUYA OKUNAKA*, TOSHIMITSU HIYOSHI, KINYA FURUKAWA, HIDEKI YAMAMOTO,
TAKAAKI TSUCHIDA, JITSUO USUDA, HIDEO KUMASAKA, JUNZOU ISHIDA,
CHIMORI KONAKA and HARUBUMI KATO
Department of Surgery, Tokyo Medical University, 6-7-1, Nishihinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Laser endoscopic surgery, especially the effectiveness ofphotodynamic therapy (PDT) using
Photofrin as a photosensitizer, has now achieved a status as effective treatment modality for
lung cancer. Twenty-six lung cancer patients received the preoperativePDT for the purpose of
either reducing the extent of resection or increasing operability. Bronchoscopical PDT is
performed with topical anesthesia approximately 48h after the intravenous injection of
2.0 mg/kg body weight of Photofrin. Operation was performed 2-9 weeks after initial PDT.
The initial purpose ofPDT, i.e. either to reduce the extent of resection or convert inoperable
disease to operable status,was achieved in22 out of26 patients treated. The survival rate ofT3
(main bronchus invasion) cases treatedby surgery alone increased significantly from50.9% to
60.0% with the application ofpreoperative PDT. This remarkable result may imply that this
new option ofPDT as preoperative laser irradiation may contribute to the management of
advanced lung malignancy.
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INTRODUCTION
Laser endoscopic surgery has now achieved a status
as effective treatment modality for lung cancer.
Especially increasing attention has been focused
on photodynamic therapy (PDT) using Photofrin.
Over the past decade, 248 patients (296 lesions) with
central type lung cancers have been treated in our
hospital. Overall complete remission (CR) was
obtained in 42.5% of the 125 lesions, partial
remission (PR) in 56.8% and no remission was
obtained in 1.0% [1]. Indications of PDT are as
follows: (1) Early stage lung cancer as a curative
purpose: among 126 early stage lesions CR was
obtained in 107 (84.9%) and 61 cases were disease
free at 2-200 months [2]. (2) Advanced lesions
for opening of bronchi: overall, "effective" opening
of bronchi was achieved in 61 out of 81 lesions
(75%) for the PDT group, as opposed to 143 of
177 (81%) for the Nd-YAG laser therapy group [3].
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(3) Preoperative laser irradiation for the purpose of
increasing operability and reducing the extent of
operation: the initial purpose of PDT, i.e., either
reduction of extent of resection or conversion of
inoperable disease to operable status, was achieved
in 11 out of 15 patients treated [4]. (4) Multiple
primary lung cancer [5].
In Japan, PDT for early stage bronchogenic
carcinoma is most common and its indications have
already been determined [6]. However, in spite of
the recent advances in the diagnostic techniques and
establishment of the mass screening system, most
lung cancers are still detected in the advanced stage.
As would be expected, better therapeutic results
were obtained in all resected cases of lung cancer
than in nonresected cases [7]. Therefore, it is neces-
sary to increase the number of operable cases of
lung cancer to improve the survival rate. In addi-
tion, even after curative resection, 15% of patients
eventually died of poor postoperative pulmonary
function. In patients with limited pulmonary func-
tion, it would therefore be beneficial to reduce the
extent of resection, thereby preserving the pulmo-
nary function. In this paper, preoperative PDT will
be discussed as one of the options to increase the
indication ofPDT.
PATIENTS AND METHODS
Patient Selection
An attempt to increase operability to reduce the
extent of operation was made in 26 lung cancer
patients ages ranging from 51 to 71 years ofwhom
5 patients had stage IA lung cancer, 2 with stage IB,
with stage IIA, 6 with stage IIB, 6 with stage IIIA, 5
with stage IIIB and with stage IV lung cancer.
Histologically, 22 had squamous cell carcinoma, 2
had adenocarcinoma, and 2had large cell carcinoma
(Table I). In cases of stage I, there were 4 cases of
tumor invasion to the bifurcation of the right upper
bronchus and trunks intermedius and 3 cases of
tumor invasion of the main bronchus. In cases
of stage II, 5 cases of tumor invaded to either right
or left main bronchus but no invasion occurred at
TABLE Preoperative PDT for lung cancer
No. of cases
Sex
Age (Year)
Histological type
Clinical stage
26
Male: 24; Female: 2
51-71; Ave.: 60.5
Squamous cell ca.: 22,
Adenoca.: 2, Large cell ca.: 2
IA 5 (main br: 1, 2nd carina: 4)
IB 2 (main br: 2)
IIA (main br: 1)
IIB 6 (main br: 6)
IIIA 6 (main br: 5, 2nd carina: 1)
IIIB 5 (main br: 2, trachea: 3)
IV (carina: 1)
the site 2 cm from the carina, and 2 cases of tumor
invasion ofcarina which were classified as stage IIB.
Therewere 3 cases with direct tracheal invasionfrom
the primary foci; 3 cases with endobronchial
polypoid tumor or invasion of the carina; and 20
cases of polypoid tumor or invasion of the main
bronchi (Table II). The invasive foci were diagnosed
endoscopically as superficial mucosal invasion.
The overall survival curves for 5 patients who
were classified as p-T3NOM0 (T3: main bronchus
invasion) received preoperative PDT and subse-
quently underwent lobectomy or sleeve lobectomy
and 11 patients who were classified as p-T3NOM0
(T3: main bronchus invasion) receiving surgical
resection alone were compared. Each case was not
randomized, however, the patients in both groups
had similar background. Patients in both groups
had squamous cell carcinoma and were treated
within same period. Age distribution was close
(averaging 60.5 years of age for the preoperative
PDT group and 59.0 years for surgery alone group).
The survival curves were measured by the Kaplan-
Meier method.
Procedure
Bronchoscopical PDT is performed with topical
anesthesia approximately 48 h after the intravenous
injection of 2.0 mg/kg body weight of Photofrin [8].
After injecting Photofrin, the patients are instructed
to avoid direct sunlight for at least two weeks. The
laser beam (630nm wavelength) is transmitted viaLUNG CANCERS TREATED WITH PDT AND SURGERY 157
TABLE II Preoperative PDT
Tumor location No. of
cases
Operation method after PDT
Trachea 3
Carina 3
Main br. or 2nd carina 20
Total 26
Sleeve lobectomy
Pneumonectomy
Tracheoplasty
Sleeve lobectomy
Pneumonectomy
Exploratory thoracotomy
Lobectomy 7
Sleeve lobectomy 10
Pneumonectomy 3
26
a quartz fiber (400mm) inserted through the
instrumentation channel of a fiberoptic broncho-
scope. The fiber tip at 1-2cm from a perpendicular
target yields a circular area of illumination of 4-
8mm. Thepower output at the fiber tipwas adjusted
to 100-400mW/cm
2 in cases using the argon dye
laser. Using the excimer dye laser, the frequency was
30 Hz and the energy was adjusted to 4 mJ/pulse.
For surface irradiation of early stage lung cancer,
illumination time generally ranged from 10-40 min,
giving energy densities of 100-800 J/cm2. However,
in advanced obstructing lung cancer, interstitial
irradiation is performed with the fiber tips inserted
into the tissue [9]. After PDT procedure, bronchial
toilet should be performed every 2 or 3 days for
week. The effectiveness ofPDTwas evaluated both
bronchoscopically and histologically 2 weeks after
the PDT, and operation was performed 2-9 weeks
after the PDT.
RESULTS
Among 3 cases with tracheal invasion, sleeve
lobectomy of the right upper lobe was performed
in case, pneumonectomy in case and tracheo-
plasty in the remaining 1. Among 3 cases of carinal
invasion by tumor, underwent right upper sleeve
lobectomy and patient underwent left pneumo-
nectomy, but the remaining patient ended up into
exploratory thoracotomy because of serious hilar
lymph node involvement. In 20 cases with tumor
TABLE III Results of preoperative PDT
Increase operability
Inoperable to operable 4
Reduce the extent of resection
Pneumonectomy to sleeve lobectomy 11
Pneumonectomy to lobectomy 7
No change 4
invasion to the main bronchi, lobectomy was
performed in 7 cases, and sleeve lobectomy in 10
cases, in order to preserve pulmonary function.
However, pneumonectomy was performed in the
remaining 3 cases because of extensive hilar lymph
node involvement (Table II). Overall, the initial
purpose of PDT, i.e., either reduction of extent of
resection or conversion of inoperable disease to
operable status, was achieved in 22 out of26 patients
treated. In 4 out of 5 patients with originally in-
operable disease, conversion to an operable condi-
tion was achieved by PDT. Although 21 patients
were originally candidates for pneumonectomy, it
became possible to reduce the extent of resection to
lobectomy or sleeve lobectomy in 18 cases (Table
III). However, 3 patients subsequently died as a
result of distant metastasis, and in 2 other cases,
recurrence was recognized.
The overall survival curves for 5 patients who
received preoperative PDT and surgery, and 11
patients who received surgical resection alone were
shown in Fig. 1. The survival rate of preoperative158 T. OKUNAKA et al.
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FIGURE The overall survival curves for 5 patients who received preoperative PDT and surgery and 11 patients who received
surgical resection alone were shown. The survival rate of preoperative PDT group and surgery alone group for 5 years was
60.0% and 50.9% respectively.
PDT group and surgery alone group for 5 years was
60.0% and 50.9% respectively.
A typical case of squamous cell carcinoma of the
lung is shown in Fig. 2. The patient, a 51-year-old
male, had a polypoid tumor obstructing the orifice
of the right main bronchus with invasion to the
lateral wall of the trachea and truncus intermedius.
This tumor was initially considered inoperable and
treated with PDT. Later on, the base of the tumor
invasion in the lateral part ofthe trachea and truncus
intermedius disappeared following PDT. Subse-
quently, upper sleeve lobectomy could be done
6 weeks after PDT.
DISCUSSION
The past decade has seen a growing acceptance of
PDT, a relativelynewmodality used in the treatment
ofcancer. This method has been used to treat a wide
variety ofmalignancies in over 3000 patients world-
wide. Approximately 90 institutions and 180 inves-
tigators throughout the world employ PDT. Five
hundred patients have undergone PDT for endo-
bronchial malignancy. There has been remarkable
consistency in results ofvarious investigator, show-
ing CR + PR rates ranging from 70% to 100% [10].
In Japan, PDT with Photofrin and excimer dye laser
obtained government approval in October 1994 and
finally obtained national insurance reimbursement
status in April 1996 11].
In our basic studies with PDT, at least cm tumor
necrosis was noted in all the cases [12]. This
observational study lead us to use PDT prepara-
tively to reduce the extent of the surgical resection
and convert inoperable cases to operable ones. In
our present study, the objective ofpreoperativePDT
was achieved in 22 out of 26 patients. The 18 casesLUNG CANCERS TREATED WITH PDT AND SURGERY 159
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FIGURE 2 A typical case of preoperative PDT. The patient, a 51-year-old male, had a squamous cell carcinoma obstructing
the orifice of the right main bronchus with invasion to the lateral wall of the trachea and truncus intermedius. Base of the tumor
invasion in the lateral part of trachea and truncus intermedius disappeared following PDT. Subsequently, sleeve upper lobectomy
could be done 6 weeks after PDT.
which were initially planned for pneumonectomy
underwent successful lobectomy. However, 3 of
them subsequently died as a result of distant
metastasis, and in 2 other cases, recurrence was
recognized. These results indicate the need for an
accurate determination of the status of the patients
before PDT. In terms of selecting patients for the
procedure, endoscopic observation, brushing and
biopsy are important. These examinations should
confirm that the lesion is invading superficially, in
which case the histological type is generally squa-
mous cell carcinoma.
In our hospital, the T3 (main bronchus invasion)
cases normally underwent surgery with a survival
rate of 50.9%. In our present study, the T3 (main
bronchus invasion) NOM0 cases which were planed
initially for pneumonectomy underwent preopera-
tive PDT and subsequently underwent lobectomy.
The survival rate in this group of patients remark-
ably increased to 60.0%. Despite the fact that the
number of cases in this study was limited, the result
is very inspiring for further study.
Various attempts have been made to develop
methods to improve the condition of lung cancer
patients so that the extent ofresection can be limited.
These include preoperative systemic chemotherapy,
bronchial arterial infusion [13] and preoperative
radiotherapy [14]. Owing to promising results with
the experimental and clinical applications of PDT,
we applied this method for the purpose of limiting
the extent of resection or for converting inoperable
status to operable. In regard to this, one of the main
advantages of PDT is that it is primarily tumor-
specific and has negligible side effects on normal
tissue.
The success from clinical trials using PDT for
treatment of cancers offers encouragement for
its future use. More stable, definitive and more160 T. OKUNAKA et al.
successful results will be obtained ifnew dyes which
distribute more equally in the tumor tissue and
deeper tissue penetration by longer wavelength
beams are used.
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